What we need to know about cancer genes

Diagnostic Cytopathology

Volumn 18, Issue 1, 1998, Pages 33-40

  Leong, Anthony S Y ^a   Leong, F Joel W M ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; COLLAGENASE; CYTOPLASM PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; GLYCOPROTEIN P; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; MATRILYSIN; NUCLEAR FACTOR; ONCOPROTEIN; PROTEIN P53; PROTEINASE; RETINOBLASTOMA PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

APOPTOSIS; CANCER GENETICS; CARCINOGENESIS; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TELOMERE; TUMOR SUPPRESSOR GENE;

CELL ADHESION MOLECULES; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; NEOPLASMS; ONCOGENES; PROTO-ONCOGENES; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0031974701     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(199801)18:1<33::AID-DC6>3.0.CO;2-V     Document Type: Review

References (29)

1. Fearon ER. Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
2. Donner P, Grieser-Wilke I, Moeling K. Nuclear localisation and DNA binding of the transforming gene product of avian myelocytomatosis virus. Nature 1982:62-266.
3. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: Differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-2497.
4. DePinho RA, Hatton K, Ferrier P. myc family genes: A dispersed multigene family. Ann Clin Res 1986;18:284-289.
5. Knudson AG. Mutation of cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:620-623.
6. Knudson AG. Hereditary cancer, oncogenes and anti-oncogenes. Cancer Res 1985;45:1437-1443.
7. Bookstein R, Allred DC. Recessive oncogenes. Cancer 1993;71:1179- 1186.
8. Hockenbery DM. Oltvai ZN,. Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an anti-oxidant pathway to prevent apoptosis. Cell 1993;75:241-251.
9. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-886.
10. Yonish-Ronach E, Resnitzky D, Lotein J. Wild type p53 induces apoptosis of myeloid leukaemia cells that are inhibited by interleukin-6. Nature 1991;352:345-347.
11. Clarke AR. Purdie DJ, Harrison RG. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-853.
12. Loeb LA. Microsatellite instability: Marker of a mutator phenotype in cancer. Cancer Res 1994;54:5059-5063.
13. Brentnall TA. Microsatellite instability: Shifting concepts in tumorigenesis. Am J Pathol 1995;147:561-563.
14. Jothy S. Flanders TY, Nowacki PM. New developments in the molecular pathology of human colonie cancer: Relevance to pathogenesis and diagnosis. Adv Anal Pathol 1996;3:343-350.
15. Urano T, Furukawa K, Shika H. Expression of nm23/NDP kinase proteins on the cell surface. Oncogene 1993;8:1371-1376.
16. Royds JA. Stephenson TJ, Rees RC. nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993;85:727-731.
17. Leone A, McBride OW, Weston A. Somatic allelicn deletion on nm23 in human cancer. Cancer Res 1991;51:2490-2493.
18. Gottesman MM, Goldstein LJ. Fojo A, Galski H, Pastan I. Expression of the multi-drug resistance gene in human cancer. In: Ronison 18, ed. Molecular cellular biology of multi-drug resistance in tumor cells. New York: Plenum Press, 1991;291:-301.
19. Kumuni P. Dewchand H, Expression of mdr I/P-glycoprotien and P110 in neuroblastoma. J Pathol 1995;175:13-22.
20. Schinkel AH, Smith JJM, van Telingen O. Disruption of the mouse mdr\ AP-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
21. Birchmcier W, Bohrens J, Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1944;1198:11-26.
22. Takeichi M. Cadherins in cancer: Implications for invasion and metastasis.Curr Opin Cell Biol 1993;5:806-811.
23. Vermuclen S, van Marck V, van Hoorde L, van Roy E, Bracke M, Marcel M. Regulation of the invasion supressor function of the cadherin/catenin complex. Path Res Pract 1996;192:694-707.
24. Takayama T, Shiozaki H, Shibamoto S, et al. βeatenm expression in human cancers. Am J Pathol 1996:148:39-46.
25. Hushainen T, Soint Y, Tutmila A, Hoyhtyu M, Oikarmen A. Auto-Harmainen H. Expression of the tissue metalloproteinase inhibitors TIMP-1 and TIMP-2 in malignant tibrous history tornas and dermatoti-bromas as studied by in situ bybridisation and immunohistoehemistry. Hum Pathol 1996;27:42-49.
26. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta L. Tissue inhibitor of metalloproteinases.2 (TIMP-2) mRNA espression in tumor cell lines and human tumor tissues. J Biol Chem 1990;265:13933-13938.
27. Testa JE. Loss of the metastatic phenotype by a human epidermoid caremorna cell line, Hep-3. is accompanied by increased expression of tissue inhibitor of metalloproteinase 2. Cancer Res 1992;52:5597-5603.
28. Poulsom R, Hanby AM, Pignatelli M, et al. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell careinomas of the skin, J Clin Pathol 1993;46:429-436.
29. Visscher DW, Hoyhtya M, Ottosen SK, et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast careinomas correlates with tumor recurrance. Int J Cancer 1994;59:339-344.